CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation Stress Echocardiography and PH: What Do the Findings Mean? Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study Expansion or contraction of stenting in coronary artery disease? Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis Regurgitant Volume/Left Ventricular End-Diastolic Volume Ratio: Prognostic Value in Patients With Secondary Mitral Regurgitation Intravascular Ultrasound Guidance vs. Angiographic Guidance in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction - Long-Term Clinical Outcomes From the CREDO-Kyoto AMI Registry 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Management of Asymptomatic Severe Aortic Stenosis: Evolving Concepts in Timing of Valve Replacement

Guideline2016 Jan 1;37(1):67-119.

JOURNAL:Eur Heart J. Article Link

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Galiè N, Humbert M, ESC Scientific Document Group. Keywords: Chronic thromboembolic pulmonary hypertension; Congenital heart disease; Connective tissue disease; Endothelin receptor antagonists; Guidelines; Heart failure; Left heart disease; Lung disease; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; Pulmonary hypertension; Respiratory failure

FULL TEXT PDF